No end in sight for anticoagulant limbo

The new generation of anticoagulants remains in limbo, amid claims the Federal Government could delay its already long-overdue funding decision until next year’s budget.

An expert review on the drugs is now with Federal Health Minister Tanya Plibersek (pictured), but there has been no confirmation of when it will be released.

Some 24,000 Australians with atrial fibrillation are currently receiving dabigatran (Pradaxa) for free from Boehringer Ingelheim, in what it is believed to be the county’s largest ever company-funded